On April 26, 2024, Akero Therapeutics, Inc. was sued for violations of the federal securities laws in the United States District Court for the Northern District of California on behalf of all purchasers of Akero common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.